TRIM52 and neoplasm: Lastly, we determined by flow cytometry whether TRIM52-targeted tumors had reduced GFP -and thus shRNA- expression (Supplementary Figure 1A), indicative of out-selection of tumor cells with the strongest TRIM52 knockdown as seen in cell culture (Figure 1C).